TY - JOUR
T1 - Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma
T2 - North central cancer treatment group results
AU - Galanis, Evanthia
AU - Buckner, Jan C.
AU - Burch, Patrick A.
AU - Schaefer, Paul L.
AU - Dinapoli, Robert P.
AU - Novotny, Paul J.
AU - Scheithauer, B. W.
AU - Rowland, Kendrith M.
AU - Vukov, Allen M.
AU - Mailliard, James A.
AU - Morton, Roscoe F.
PY - 1998/9
Y1 - 1998/9
N2 - Purpose: Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. Patients and Methods: Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen. Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14. Cycles were repeated every 28 days. Results: Of 61 patients assessable for response, eight responded (13%), with one complete response (CR). Responses were as follows: low-grade gliomas, 19%; anaplastic astrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%. The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/μL in 23% and platelet nadirs less than 25,000/μL in 13% of patients. Two patients died of infection in the setting of neutropenia. Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severe dermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P = .01) and time to progression (P = .008), while PS and grade were the most important predictors of survival (P = .002 and .05, respectively). Conclusion: This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively). In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival.
AB - Purpose: Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. Patients and Methods: Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen. Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14. Cycles were repeated every 28 days. Results: Of 61 patients assessable for response, eight responded (13%), with one complete response (CR). Responses were as follows: low-grade gliomas, 19%; anaplastic astrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%. The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/μL in 23% and platelet nadirs less than 25,000/μL in 13% of patients. Two patients died of infection in the setting of neutropenia. Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severe dermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P = .01) and time to progression (P = .008), while PS and grade were the most important predictors of survival (P = .002 and .05, respectively). Conclusion: This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively). In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival.
UR - http://www.scopus.com/inward/record.url?scp=0031692882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031692882&partnerID=8YFLogxK
U2 - 10.1200/JCO.1998.16.9.2953
DO - 10.1200/JCO.1998.16.9.2953
M3 - Article
C2 - 9738563
AN - SCOPUS:0031692882
SN - 0732-183X
VL - 16
SP - 2953
EP - 2958
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 9
ER -